Amarin (AMRN) Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AMRN shares.
View AMRN analyst ratings or view top-rated stocks.

2 brokers have issued 12 month target prices for Amarin's stock. Their AMRN share price forecasts range from $2.00 to $3.00. On average, they anticipate the company's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 95.3% from the stock's current price.
View analysts price targets for AMRN or view top-rated stocks among Wall Street analysts.

Amarin's stock was trading at $1.21 at the start of the year. Since then, AMRN shares have increased by 5.8% and is now trading at $1.28.
View the best growth stocks for 2023 here.

Amarin saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 20,980,000 shares, a decrease of 12.8% from the April 30th total of 24,070,000 shares. Based on an average trading volume of 3,200,000 shares, the short-interest ratio is presently 6.6 days.
View Amarin's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our AMRN earnings forecast.

Amarin Co. plc (NASDAQ:AMRN) posted its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. The biopharmaceutical company earned $142 million during the quarter, compared to analysts' expectations of $161.29 million. Amarin had a negative net margin of 25.16% and a negative trailing twelve-month return on equity of 15.45%. The company's revenue was down 8.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.02) EPS.

ETFs with the largest weight of Amarin (NASDAQ:AMRN) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), Global X Aging Population ETF (AGNG), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB),

43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com. John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

Amarin's stock is owned by a number of institutional and retail investors. Top institutional investors include Two Sigma Investments LP (1.38%), DG Capital Management LLC (1.36%), Sarissa Capital Management LP (1.22%), 13D Management LLC (1.03%), Acadian Asset Management LLC (0.82%) and Two Sigma Advisers LP (0.71%). Insiders that own company stock include David M Stack, John F Thero, Joseph S Zakrzewski, Michael Wayne Kalb, Olsen Per Wold and Steven B Ketchum.
View institutional ownership trends.

Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMRN stock can currently be purchased for approximately $1.28.

Amarin (NASDAQ:AMRN) has a market capitalization of $516.90 million and generates $369.19 million in revenue each year. The biopharmaceutical company earns $-105,800,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis.

The company employs 560 workers across the globe.

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The official website for the company is www.amarincorp.com. The biopharmaceutical company can be reached via phone at (531) 669-9020 or via email at investor.relations@amarincorp.com.